Background: Tobacco smoking creates DNA damage, inducing mutations and potentially altering the tumor immune microenvironment. These types of genetic and immune microenvironment alterations are critical factors known to affect tumor response to immunotherapy. Here we analyze the association between the mutational signature of tobacco smoking, tumor mutational load, and metrics of immune activity in squamous cell carcinomas arising in the head and neck and lung. Methods: Using RNA and DNA sequencing data from The Cancer Genome Atlas head and neck (HNSC; n ¼ 287) and lung (LUSC; n ¼ 130) squamous cell carcinoma data sets and two independent gene expression data sets (HNSC, n ¼ 136; LUSC, n ¼ 75), we examined associations between the mutational smoking signature, mutation count, immune cell infiltration, cytolytic activity, and interferon-c signaling.
Tobacco smoking is a risk factor for the development of cancers of the lung, head and neck, and other sites. Tobacco carcinogens create a specific mutational signature in tumors and are associated with increased overall mutation count (1) . It is also likely that immunologic sequelae of smoking may contribute to the development of cancer, with both pro-inflammatory (2) and immunosuppressive (3) effects having been described. Both of these factors-mutational load and the tumor immune microenvironment-have been associated with tumor response to immunotherapy (4, 5) . Clinical data indicate that smokers with lung cancer have higher response rates to immune checkpoint inhibitor therapy (6, 7) , while smokers with head and neck cancer tend to have lower response rates (8) .
Because only a minority (10%-15%) of patients with head and neck and non-small cell lung cancer experience clinical benefit with immune checkpoint inhibitor therapy, there is a need to identify factors that determine clinical response. Identifying predictive biomarkers can maximize clinical benefit for patients by guiding choice of therapy, and potentially illuminate novel biologic mechanisms.
In order to better understand why the majority of smokingrelated tumors do not respond to immune checkpoint inhibitor therapy, we analyzed the mutational signature of smoking and its association with tumor mutational load and the immune microenvironment-parameters that modulate immunotherapy response-in squamous cell carcinomas arising in the head and neck (HNSC) and lung (LUSC).
Methods

Data Sources
The gene-level RSEM-normalized RNA-sequencing (RNAseq) data for The Cancer Genome Atlas (TCGA) head and neck (HNSC, n ¼ 287) and lung (LUSC, n ¼ 130) squamous cell carcinoma cohorts (9, 10) , and other cancer types were obtained from the UC Santa Cruz cancer genomics browser (https://genomecancer.ucsc.edu) (11) . We calculated the cytolytic (CYT) score (12) , enrichment in interferon-c (IFNg) signaling (via gene set enrichment analysis using the REACTOME IFNg geneset; http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_ INTERFERON_GAMMA_SIGNALING), and ESTIMATE Immune Score (13) for each sample. Additional data sets for HNSC and LUSC, including raw count RNAseq level 1 files, exome sequencing data in level 3 curated MAF files, clinical data, and Affymetrix SNP6 copy number data, were also downloaded from the Broad Institute Firehose pipeline (https://gdac.broadinstitute.org). Sample purity was inferred from SNP6 copy number array data in ASCAT (14) . For the mutational smoking signature, we used the published deconstructSigs mutational signature 4 data (15), representing the mutational pattern associated with tobacco carcinogens such as benzo[a]pyrene, characterized mainly by C>A mutations (16) . The numerical signature weight represents the contribution of the process to the mutations in a given tumor sample.
Additional published gene expression microarray data sets were analyzed. The expression matrix for the head and neck cancer data set (n ¼ 138, of which 136 had smoking history) of Walter et al. (17) was downloaded from the Gene Expression Omnibus (data set GSE39366) and comprised backgroundcorrected and LOESS-normalized data from customized Agilent 4x44K arrays. The expression matrix for the lung squamous cell cancer data set (n ¼ 75) of Lee et al. (data set GSE8894) (18) comprised GC-content robust multiarray averaging-normalized data from Affymetrix HG U133 Plus 2.0 arrays. Probes were filtered by selecting the probe with the median absolute deviation for the gene, and normalized values were used for calculation of the ESTIMATE Immune Score. Because these data were obtained on different platforms and normalized independently, the results of immune metrics are not comparable across data sets.
Bioinformatic and Statistical Analyses
The primary hypothesis to be tested was whether there was an association between the mutational smoking signature and immune metrics. Correlations with immune metrics were performed with a nonparametric Spearman coefficient, and multivariable least-squares regression was used to adjust for purity. Power calculations indicated that the HNSC cohort was powered to identify a Spearman q of .165, and the LUSC cohort q value was .245, at an a of .05 and 1-b of .80. For dichotomous comparisons, HNSC and LUSC samples were ranked together by signature 4 and classified as "smoking-high" or "smoking-low" based on highest and lowest quartiles, respectively, such that the same numerical thresholds were used for both HNSC and LUSC. Comparisons of independent sample means of nonnormally distributed data such as the tobacco signature were performed with the two-tailed Wilcoxon rank-sum test, and comparisons of normally distributed immune metrics were performed with the two-tailed t test. Multivariable analyses in HNSC that included tumor subsite or human papillomavirus (HPV) status were limited to 215 cases with nonoverlapping single anatomic subsites and known HPV status, as delineated in Supplementary Tables 1 and 2 (available online). Analysis of correlations between clinical smoking and immunologic metrics in independent expression data sets (17, 18) , clinical response rates in patients, and the interaction term in the multivariable survival model were directional hypotheses evaluated with a single-tailed t test. Survival analyses of overall survival, where events are defined as death from any cause, utilized univariate or multivariable Cox regression. The proportional hazards assumption was assessed using log(-log(survival)) plots for different strata.
Differentially expressed genes (DEGs) were identified using RNAseq raw counts in DESeq2(19) with a false discovery rate (FDR)-adjusted P value of less than .10. For HNSC, the calculation of DEGs incorporated anatomic subsite as a covariate and included HPV-negative cases only. Pathway enrichment was then assessed with input of DEGs with an FDR P value of less than .10 into Ingenuity Pathway Analysis. An orthogonal pathway analysis was also carried out with gene set enrichment analysis (GSEA), inputting gene expression data for smokinghigh and smoking-low LUSC and HNSC (HPV-negative only) tumors and plotting results by normalized enrichment score and -log (FDR-adjusted P value).
Scatterplot regression lines were generated with LOESS regression using Epanechikov kernel. Analyses were performed in R 3. 
Results
We analyzed the mutational smoking signature and tumorinfiltrating immune microenvironment in several cancer types sequenced by the TCGA. The smoking signature represents the contribution of the tobacco-associated mutational process to the mutations in a sample and is most prevalent in head and neck and lung cancers. Further analyses were performed in HNSC and LUSC (9, 10) . A nonzero smoking signature was more prevalent in LUSC than in HNSC (89.2% vs 76.7%, P ¼ .003) (Supplementary Figure 1 and Supplementary Table 1 , available online), correlating with clinical smoking history (pack-years) in HNSC (Spearman q ¼ .52, P < .001, n ¼ 232 with complete data) but not in LUSC (q ¼ -.02, P ¼ .89, n ¼ 127) (Supplementary Figure 2 , available online), consistent with prior data and the low numbers of nonsmokers in LUSC (<5% of LUSC patients were never-smokers) (1, 6) . HNSC and LUSC tumors were ranked together by smoking signature and classified in highest ("smoking-high" > .394) and lowest ("smoking-low" < .099) quartiles (Supplementary Tables 2 and 3, available online Table 4 , available online). In contrast, the smoking signature was not prognostic in LUSC (HR ¼ 1.02, 95% CI ¼ 0.71 to 1.46, P ¼ .92) ( Figure 1C ) or when controlling for adjuvant therapy (Supplementary Table 4 , available online). A statistically significant interaction between cancer type and smoking signature (P ¼ .03) (Supplementary Table 4 , available online) indicated that the prognostic impact of smoking differs between HNSC and LUSC.
To examine the effects of smoking on the tumor immune microenvironment, we interrogated levels of immune activation and infiltration in RNAseq data, analyzing three immune metrics: cytolytic activity (CYT score, incorporating cytolytic effectors of CD8þ T cells: GZMA, and PRF1), IFNg signaling, and ESTIMATE Immune Score. Across eight TCGA cancer types, these three orthogonal measures correlated closely, suggesting that they each reflect aspects of tumor immunity (Supplementary Figure 3 , available online).
In HNSC, most (47/73, 64.4%) smoking-high tumors arose in the larynx, consistent with the strong etiologic link between smoking and laryngeal cancers. We performed further analyses comparing HNSC in all subsites, HNSC in the larynx only, and LUSC. Smoking was associated with increasing mutation count in HNSC (q ¼ .33,
and LUSC (q ¼ .49, P ¼ 2.80Â10
À9
) tumors (Figure 2A ). Mutational load was not consistently associated with trends in tumor immune infiltration in HNSC or LUSC (Supplementary Figures 3  and 4 , available online), consistent with prior data in LUSC (21) .
In HNSC (all subsites), a higher smoking signature was consistently associated with lower levels of immune infiltration (q We confirmed these associations in independent HNSC and LUSC expression data sets (17, 18) . The mutational smoking signature was not discernible in these samples without exome sequencing, so immune metrics were correlated with clinical smoking history. In the HNSC data set of Walter et al. In the TCGA HNSC (HPV-negative) and LUSC data sets, differentially expressed genes (DEGs) were identified by comparing smoking-high to smoking-low tumors (with HNSC subsite as a covariate) (Supplementary Tables 6 and 7 and Supplementary  Figure 11 , available online). These DEGs were enriched for genes involved in nicotine degradation, xenobiotic metabolism, and glutathione-mediated detoxification pathways. Using Ingenuity Pathway Analysis to determine directionally altered pathways, smoking was associated with immunosuppressive pathways in HNSC, but not in LUSC: repression of interferon signaling (P ¼ .01), type I interferon response via interferon regulatory factor (P ¼ .03), leukocyte (P ¼ 2.63Â10
À4
) and granulocyte (P ¼
5.25Â10
À4 ) function ( Figure 3A ; Supplementary Tables 8 and 9 , available online). Using an orthogonal pathway analysis technique (Gene Set Enrichment Analysis), a similar distinction was seen: there was a strong pro-inflammatory phenotype in LUSC and an immunosuppressive phenotype in HNSC ( Figure 3B ). Table 10 and Supplementary  Figure 12 , available online). These immunologic DEGs represented four of the six genes in the previously described "IFNg signature," which predicts response to anti-PD1 treatment (Supplementary  Table 11 , available online) (5), supporting the likely relevance of these findings to immunotherapy response.
Heavy smoking has been associated with TP53 mutations, both in lung and head and neck cancers (22, 23) . Indeed, the smoking signature was higher in TP53-mutated vs TP53 wildtype tumors, both in HNSC (0.35 vs 0.25, P ¼ .002) and LUSC (0.23 vs 0.13, P ¼ .13). The trend was not statistically significant in LUSC, likely due to small numbers of TP53 wild-type tumors (n ¼ 6). TP53-mutated HNSC tumors had statistically significantly lower levels of immune infiltration (Immune Score 337 vs 624, P ¼ .003), while TP53-mutated LUSC tumors demonstrated an opposite trend (Immune Score 626 vs 360, P ¼ .38). The other commonly mutated genes in HNSC and LUSC, which have not been linked with tobacco exposure, were not associated with immune infiltration (Supplementary Table 5 , available online). The only gene statistically significantly associated with higher levels of immunity was CASP8 (HNSC Immune Score 820 vs 443, P ¼ .04; LUSC Immune Score 1574 vs 594, P ¼ .04). This is consistent with prior findings that CASP8 was the most enriched mutation in tumors with high cytolytic activity (12) .
Taken together, these data are consistent with reported response rates to immune checkpoint inhibitor therapies, which are higher among smokers with lung cancer but lower among smokers with HNSC (6-8). Because published HNSC response data stratified by HPV and smoking status are not available, we analyzed the clinical response data of 81 HNSC patients treated at our institution with anti-PD-1/PD-L1 drugs. We found that the rate of clinical benefit (complete/partial response or stable disease) was statistically significantly higher in never-smokers compared with current/former smokers (57.1% vs 33.3%, P ¼ .03). This trend remained statistically significant when analysis was limited to HPV-negative tumors (P ¼ .02) (Supplementary Table 12 , available online).
Discussion
The mutagenic effects of cigarette smoking operate similarly in lung and head and neck squamous cell carcinomas. In both cancer types, tumors with an increasing proportion of mutations attributable to smoking have higher overall mutational loads. However, the clinical and immunologic correlates of smoking differ in these two squamous cell carcinoma types. In HNSC, the mutational smoking signature is associated with poorer survival and strong immunosuppressive effects, which are seen even adjusting for subsite and HPV status. In contrast, in LUSC, smoking is associated with a more inflamed tumor microenvironment.
These findings are consistent with clinical data indicating that smokers with lung cancer tend to have higher response Overall survival probability A B C D Figure 2 . Scatterplots of associations between genetic smoking signature and (A) tumor mutational load (log-transformed), (B) cytolytic score (log-transformed), (C) enrichment in interferon-c signaling, and (D) overall immune infiltration, as measured by ESTIMATE Immune Score. Correlations for head and neck squamous cell carcinoma (HNSC; all sites), HNSC (larynx only), and lung squamous cell carcinoma were determined using Spearman correlation (q with P value) and curve fitting with LOESS regression. CYT ¼ cytolytic; H&N ¼ head and neck; SCC ¼ squamous cell carcinoma.
rates to immune checkpoint inhibitors. For example, Rizvi et al.
reported that in non-small cell lung cancer patients (both squamous cell and adenocarcinoma) treated with anti-PD-1 therapy, the mutational smoking signature was a more precise determinant of response than clinical smoking history. Objective response rates to therapy were substantially higher among smoking signature-high tumors, compared with smoking signature-low tumors (56% vs 17%, P ¼ .03) (6) . Although clinical smoking history seems to be less predictive than the mutational smoking signature, in the phase III trial of firstline nivolumab in stage IV non-small cell lung cancer, never-smokers had a statistically significantly higher likelihood of progression or death with nivolumab therapy (HR ¼ 2.51, 95% CI ¼ 1.31 to 4.83) vs chemotherapy, compared with former or current smokers (HR ¼ 1.03-1.14) (7). Data in HNSC are more limited: the only available data of HNSC patients treated with immune checkpoint blockade with clinical smoking history are from the phase III trial of nivolumab in patients with recurrent HNSC. Among these patients, the survival benefit associated with nivolumab was numerically lower in current/former smokers (HR ¼ 0.71, 95% CI ¼ 0.52 to 0.99) compared with never-smokers (HR ¼ 0.58, 95% CI ¼ 0.32 to 1.06) (8) . Although these data were not stratified by HPV status, response rates were similar in HPVþ and HPVtumors (15.9% vs 14.5%) (24) . Our analysis of 81 HNSC patients treated at our institution provides additional support for the higher response rates seen in never-smokers. Future genomic analyses that incorporate the mutational smoking signature will be able to define the effects of smoking in both disease sites more precisely. Interestingly, the association between patient-reported smoking history and the smoking signature was stronger in HNSC than in LUSC. This may be due to the very high prevalence of tobacco exposure in LUSC patients ($97%) compared with HNSC patients (81%), attenuating the power of this comparison. The vast majority (80%) of LUSC patients were actually former/reformed smokers, a population in which the associations between clinical smoking history and the smoking signature may be obscured by patient recollection and other mutational processes occurring over intervening years (1) .
Smoking has direct suppressive and pro-apoptotic effects on T cells, linked to reactive oxygen and nitrogen species (3). The immunosuppressive effects of tobacco smoke on T cells may be counterbalanced in the lung context by strongly proinflammatory effects, which have been well described in chronic obstructive pulmonary disease (2, 25) . In the context of lung cancer (adenocarcinomas), smoking-associated transversions have been found to be associated with higher levels of immune markers (such as tumor PD-L1 and granzyme B staining) (26) .
Comparable chronic airway inflammation is not common in the head and neck, where immunosuppressive mechanisms may instead dominate. These pro-and anti-immunity effects of smoking coexist with the enrichment in immunogenic neoantigens that would be anticipated with smoking mutagenicity, and which is seen in both HNSC and LUSC. It is likely that, in LUSC, the combined effects of increased neoantigen load and an inflamed microenvironment account for the markedly higher response rates to immunotherapy observed in smokers. In contrast, in HNSC, the increase in immunogenic neoantigen load associated with smoking may be countered by a more immunosuppressive microenvironment.
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Pathways altered in smoking-high tumors These findings raise the possibility that tumor mutational burden, which is highly predictive of immunotherapy response in lung cancer, may have lower predictive value in head and neck cancer. Preliminary data from pembrolizumab-treated HNSC patients suggest that gene expression-based measures of tumor inflammation are more predictive of response than mutational load (27) . These hypotheses will require further investigation.
We found that smoking signature was associated with TP53 mutations, but not other driver mutations, in HNSC and LUSC (22, 23) . Among statistically significantly mutated genes, CASP8 was the only gene in which mutations were associated with the status of the immune microenvironment. In both HNSC and LUSC, CASP8 mutations were associated with statistically significantly higher immune infiltration, consistent with prior pancancer analyses of cytolytic activity (12) . CASP8-mutated tumor cells, which are deficient in the extrinsic apoptosis pathway, may be able to evade cytotoxic T-cell killing (28) and thereby undergo positive selection in highly immune-enriched environments.
There are important limitations to this analysis. These associations cannot implicate causality, for example, whether effects are mediated by T cells, neoantigen presentation, or other mechanisms. While consistent with initial clinical observations, further prospective data will be needed to definitively connect the smoking signature with immunotherapy response. The mutational smoking signature is likely to be more strongly correlated with immunotherapy response than clinical smoking history, as has been seen in lung cancer (6) .
This study demonstrates the importance of the mutational smoking signature as an indicator of both tumor mutational burden and smoking-associated modulation of the immune microenvironment. These associations vary by cancer site. Future analyses will help to define the additional value of the smoking signature, combined with other factors such as tumor mutational load, PD-L1 expression, and measures of the T-cell inflamed microenvironment, in patients with smoking-associated cancers who are treated with immunotherapy. Our data indicate that it will be important to assess the effects of smoking separately in different cancer types.
The etiology of smoking-associated cancers is attributable to both mutagenic and immunomodulatory mechanisms. These data illuminate the profound yet context-dependent effects of smoking on the tumor immune microenvironment of squamous cell cancers. Smoking can exert either immunosuppressive or pro-inflammatory effects on the microenvironment, which appear to vary depending on anatomic site. Because both mutational load and immune infiltration affect the likelihood of ARTICLE clinical response to immune checkpoint inhibitors, these data will have relevance for future clinical investigation of immunotherapy in smoking-related cancers, particularly among the increasing number of tumors now being studied with genomic profiling.
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